#114
Downstaging of a gastroenteropancreatic neuroendocrine tumor after combination therapy of temozolomide, Bevacizumab and long-acting somatostatin analogs
Introduction:
Patients with gastroenteropancreatic endocrine (GEP) tumors and progressive disease have been treated with several chemotherapeutic regimens with variable responses and considerable toxicity. Recent studies have shown that GEP tumors may respond to therapy with anti-angiogenic agents, mainly as a result of their increased vascularity.
Conference:
7th Annual ENETSConcerence (2010)
Presenting Author:
KALTSAS G
Authors:
Antoniou S,
Kanakis G,
Zilos A,
Thomas D,
Tzavaris N,
Keywords:
GEPNETs,
temozolomide,
bevacizumab,
somatostatin analogue,
#59
Incidence and clinical significance of adrenal masses in patients with gastrenteropancreatic neuroendocrine tumors
Introduction:
The widespread application of modern imaging modalities, mainly computerized tomography (CT) and magnetic resonance imaging (MRI), has revealed a 2-3% incidence of inadvertently discovered adrenal masses, the majority of which are non-functioning benign adrenal adenomas. In the presence of a known malignancy, such lesions have a more than 30% incidence of being metastases. As patients with gastrenteropancreatic neuroendocrine tumors (GEP-NETS) have mainly well-differentiated and slow-growing tumors and are subject to routine abdominal imaging for disease staging or during follow-up, it is important to study the incidence and significance of such lesions based on the recently introduced TNM classification system.
Conference:
7th Annual ENETSConcerence (2010)
Presenting Author:
Authors:
Kanakis G,
Antonioy S,
Thomas D,
Zilos A,
Roussaki P,
Keywords:
neuroendocrine tumors,
adrenal incidentalomas,
staging,
#55
Metronomic combination therapy including temozolamide, bevacizumab and somatostatin analogue for the treatment of malignant gastroenteropancreatic neuroendocrine tumors
Introduction:
Malignant gastroenteropancreatic neuroendocrine tumors (GEPNETS), mainly carcinoids, are not considered to be particularly chemotherapy-sensitive to conventional chemotherapeutic schemes. Long-standing evidence suggests these tumors to be highly vascularised and responsive to antiangiogenic strategies. Newest reports demonstrate benefit by the use of temozolamide, an oral alkylating agent similar to intravenous dacarbazine. The DNA repair enzyme O6-alkylguanine–DNA alkyltransferase (AGAT) confers cancer cell resistance to O6-alkylating agents such as temozolamide through its ability to remove methyl/alkyl groups from the O6-position of guanine, thus correcting drug-induced DNA damage.
Conference:
7th Annual ENETSConcerence (2010)
Presenting Author:
Authors:
Koumarianou A,
Zilos A,
Syrios J,
Kanakis G,
Antoniou S,
Keywords:
GEPNETs,
temozolamide,
bevacizumab,
somatostatin analogue,
